ArticleArchives of medical science : AMS2026
Hyperbaric oxygen effects on the alveoli-capillary unit in a murine model of pulmonary arterial hypertension.
Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pulmonary hypertension (PH) is an increase in the normal value of systolic pressure of the pulmonary artery, frequently due to congenital heart diseases being its treatment the correction of this defects; alternatively, hyperbaric oxygen (HBO) has shown beneficial effects facilitating neovascularisation and decreased vascular resistance. An experimental study was designed to determine the effect of HBO on the alveoli-capillary unit in a murine model of irreversible pulmonary hypertension (IPAH) induced with monocrotaline. Material and methods: Four groups of 10 Wistar rats each were considered: A (control), B (HBO), C (IPAH), and D (IPAH+HBO). HBO was administered at 2 atm, 1 h daily, for 15 days. At the end of this time, systolic pulmonary artery pressure (PAP) was measured, followed by histologically quantification of the number of cells, vascular buttons, and neoformation vessels employing the immunochemistry detection of hypoxia-induced factor-1 (HIF-1), vascular endothelial growth factor (VEGF), and CD34, respectively. Results: Histologically, this matches with an increase of the average number of positive HIF-1 cells, and an increase in VEGF-positive vascular buttons in group D rats compared with those of group C. The number of CD34-positive neovessels was similar in groups C and D, but in the latter group the number of capillary vessels was more significant. Conclusions: This suggests that angiogenesis and vasculogenesis were induced by HIF-1, and it has been achieved due to an early effect of HBO therapy. Presumably, neovessels were formed between days 5 and 10 following HBO therapy, but more experimental studies are required to test this hypothesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.